تفاعل #1779953

ord-03a4c91261e04da086da6570ec19fd26

معادلة التفاعل

CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(Cl)nc3s2)CC1
5-Chloro-2-(4-methanesulfonyl-piperazin-1-ylmethyl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine
CC1(C)OB(c2cnc3ccccc3c2)OC1(C)C
3-(4,4,5,5-tetramethyl-1,3,2,-dioxaborolan-2-yl)quinoline
CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc5ccccc5c4)nc3s2)CC1
112
المردود 46.0%
CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc5ccccc5c4)nc3s2)CC1
4-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-5-(quinolin-3-yl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine
المردود 46.0%

ظروف التفاعل

الظروف التفصيلية
See reaction.notes.procedure_details.

المعالجة

  1. 1
    أخرىThe product was purified by reverse phase HPLC

الإجراء التجريبي

5-Chloro-2-(4-methanesulfonyl-piperazin-1-ylmethyl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine (130 mg) was reacted with 92 mg of 3-(4,4,5,5-tetramethyl-1,3,2,-dioxaborolan-2-yl)quinoline via General Procedure A. The product was purified by reverse phase HPLC to yield 72.6 mg of 112. MS (Q1) 526.2 (M)+.

المصدر

DOI: 10.6084/m9.figshare.5104873.v1براءة الاختراع: US08158626B2uspto-grants-2012_04